Asco, Food

In Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.The study is considered to be the first metastatic pancreatic cancer study in nearly a decade with a successful overall survival outcome.The first author of the oral abstract outlining the findings presented at the ASCO Gastrointestinal Cancers Symposium on January 20 in San Francisco is Dr. Zev Wainberg, co-director of the UCLA Health GI Oncology Program and a researcher at UCLA Jonsson Comprehensive Cancer Center."There have been several chemotherapy regimens used to treat newly diagnosed, metastatic pancreas cancer, also called stage 4, but there have been few head-to-head comparisons to see which regimen would produce a longer overall survival," Wainberg said. "These trials help answer critically important treatment questions for all who treat pancreas cancer."For the study, 770 patients were randomly assigned to one of two chemotherapy regimens. Patients in the four-drug group had an overall survival of 11.1 months, compared with 9.2 months for those in the two-drug arm. Progression-free survival also increased with the four-drug therapy - 7.4 months versus 5.6 months with the two-drug regimen. Several side effects, such as diarrhea, nausea and low levels of potassium, were more common in patients taking the four-drug treatment, but anemia and low levels of white blood cells were more common in those taking the two drugs.The four-drug regimen consisted of liposomal irinotecan, 5-fluorouracil/leucovorin and oxaliplatin - together referred to as NALIRIFOX. The two-drug therapy consisted of nab-paclitaxel and gemcitabine."This study indicates that the more aggressive chemotherapy approach should be considered for those patients who are able to tolerate it," Wainberg said. "Metastatic pancreas cancer has long been recognized as a very difficult type of cancer to treat, but this study represents a possible new reference standard for current treatment and for future research and drug development."( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

AscoFOLLOW

Asco, Latest News

Chennai, Feb 7 The district education department has suspended two teachers of a government lower primary school in Tamil ... ...

Chennai, Feb 7: At their homes, vegetarians spent 5 per cent more per thali in January 2024 as compared ... ...

New York, June 8 Walking for half an hour daily as well as practising a soft form of ... ...

Massachusetts [US], June 2 : Researchers discovered that 42 percent of patients with metastatic brain cancer benefited from the ... ...

New Delhi (India), April 20: The key to achieving a healthy, glowing complexion lies in a consistent skincare routine. However, ... ...

New Delhi [India], April 7 : Ramzan is all about enhancing one's spiritual credence and detoxing the body by ... ...

According to clinical trial results, immunotherapy after surgery increased bladder cancer patients' chance of staying cancer-free compared to patients ... ...

In Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall ... ...